Osteoporosis following heart transplantation and immunosuppressive therapy

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

4 !!Citations (SciVal)


Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.

Sidor (från-till)232-239
TidskriftTransplantation Reviews
Tidigt onlinedatum2017 aug 12
StatusPublished - 2017

Ämnesklassifikation (UKÄ)

  • Kardiologi


Utforska forskningsämnen för ”Osteoporosis following heart transplantation and immunosuppressive therapy”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här